ViewRay, a US-based developer of radiation therapy technology for the treatment of cancer, has raised $15m of a planned $17.4m round, according to a regulatory filing.
The company’s backers include Fidelity Biosciences, which invests in healthcare on behalf of mutual fund manager Fidelity Investments, and Siemens Venture Capital, the corporate venturing division of Germany-based industrial conglomerate Siemens, as well as venture capital firms Aisling Capital, Kearny Venture Partners and OrbiMed Advisors.
In March 2012, ViewRay raised a $45m series C round, taking total fundraising to an estimated $73m. Fidelity and the three VCs provided $25m to ViewRay’s series B round in 2008 while the firm closed its series A round the year before at $3m mainly from private individuals. ViewRay was founded in 2004.